Cd19 - CD19 antigen Gene

Species: Mus musculus

Gene Type: protein coding
Gene ID: 12478

Summary

Involved in several processes, including B-1 B cell differentiation; positive regulation of phosphatidylinositol 3-kinase activity; and positive regulation of release of sequestered calcium ion into cytosol. Acts upstream of or within B cell receptor signaling pathway. Located in external side of plasma membrane. Is integral component of plasma membrane. Is expressed in liver and spleen. Human ortholog(s) of this gene implicated in common variable immunodeficiency. Orthologous to human CD19 (CD19 molecule). [provided by Alliance of Genome Resources, Apr 2022]

Cd19 Products (2)

mRNA Protein Name
NM_001357091.2 NP_001344020.1 B-lymphocyte antigen CD19 isoform 2 precursor
NM_009844.3 NP_033974.2 B-lymphocyte antigen CD19 isoform 1 precursor
Protein Preferred Names Protein Names

B-lymphocyte antigen CD19

  • differentiation antigen CD19

Recombinant Cd19 Proteins

Art. -Nr. Produktname Accession Reinheit
HY-P74328 CD19 Protein, Mouse (HEK293, His) P25918 (R19-G287) ≥ 90%, as determined by reducing SDS-PAGE.
HY-P77527 CD19 Protein, Mouse (Biotinylated, HEK293, His) P25918 (G17-G287) ≥ 90%, as determined by reducing SDS-PAGE.

Related Agents

  • Approval
  • Clinical Phase
  • Pre-clinical Phase

Approval

Inhibitory Antibodies (2)
Art. -Nr. Produktname Wirkung
Reinheit Rare Diseases
HY-P9963 Blinatumomab Inhibitor 98.78% Unkown
HY-P99113 Inebilizumab Inhibitor 99.00% Unkown

Clinical Phase

Inhibitory Antibodies (13)
Art. -Nr. Produktname Wirkung
Reinheit Phase
HY-P991028 Surovatamig Inhibitor 99.89% Phase 3
HY-P99711 Loncastuximab Inhibitor ≥99.0% Phase 3
HY-P99761 Obexelimab Inhibitor 99.99% Phase 3
HY-P99285 Denintuzumab Inhibitor ≥99.0% Phase 2
HY-P990017 Englumafusp alfa Inhibitor 99.93% Phase 2
HY-P99914 Emfizatamab 95.495% Phase 2
HY-P991900 LY3541860 Inhibitor ≥99.0% Phase 2
HY-P990729 Budoprutug 95.91% Phase 2
HY-P99868 Duvortuxizumab ≥99.0% Phase 1
HY-P990694 Zeripatamig ≥99.0% Phase 1
HY-P991176 RG-6333 Agonist 98.05% Phase 1
HY-P991898 IASO-782 Inhibitor / Phase 1
HY-P991231 DI-B4 Inhibitor / Phase 1

Pre-clinical Phase

Bioactive Molecules (2)
Art. -Nr. Produktname
Wirkung
Reinheit
Rare Diseases
HY-153084A CD19 CAR mRNA (Human) / Unkown
HY-153085 CD19 CAR circRNA / Unkown
Inhibitory Antibodies (10)
Art. -Nr. Produktname
Wirkung
Reinheit
Rare Diseases
HY-P99113A Inebilizumab (FUT8-KO) 99.84% Unkown
HY-P99976 Anti-Mouse CD19 Antibody (1D3) Inhibitor 98.778% Unkown
HY-P990870 Anti-CD19 Antibody (4G7) Inhibitor 98% Unkown
HY-P990571 Coltuximab Inhibitor 98.43% Unkown
HY-P990349 Anti-CD19 Antibody Inhibitor 99.91% Unkown
HY-P991542 GBR-401 Inhibitor / Unkown
HY-P991897 Anti-CD19 Antibody (hA19) / Unkown
HY-P99577 Taplitumomab / Unkown
HY-P991899 IKS03 Antibody / Unkown
HY-P991839 Anti-CD19 Antibody (FMC63) Inhibitor 95.56% Unkown

Orthologs Information

Species Symbol Source ID
Homo sapiens Cd19 NCBI NCBI:930